Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Acquisitions & Divestments (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Change in Acquisitions & Divestments for 13 consecutive years, with $24.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 10.9% to $24.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $117.5 million, a 27.68% decrease, with the full-year FY2024 number at $139.8 million, up 344.77% from a year prior.
  • Change in Acquisitions & Divestments was $24.5 million for Q3 2025 at Theravance Biopharma, up from $20.3 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $115.5 million in Q1 2021 to a low of $17.0 million in Q3 2022.
  • A 5-year average of $42.6 million and a median of $40.1 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 673.51% in 2021, then crashed 58.01% in 2022.
  • Theravance Biopharma's Change in Acquisitions & Divestments stood at $115.5 million in 2021, then plummeted by 57.32% to $49.3 million in 2022, then grew by 27.21% to $62.7 million in 2023, then crashed by 36.14% to $40.1 million in 2024, then tumbled by 38.83% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Change in Acquisitions & Divestments are $24.5 million (Q3 2025), $20.3 million (Q2 2025), and $32.6 million (Q1 2025).